Monoket

Coronary Disease, Chest Pain
Treatment
3 Active Studies for Monoket

What is Monoket

Isosorbide mononitrateThe Generic name of this drug
Treatment SummaryIsosorbide mononitrate is a medication used to treat chest pain from coronary artery disease. It is an organic nitrate that relaxes the smooth muscles in arteries and veins, which helps reduce the workload of the heart. Isosorbide mononitrate is available in oral tablets and extended-release forms under the brand names ISMO and Monoket. It was approved by the FDA in 1991 and is generally well-tolerated.
Monoketis the brand name
image of different drug pills on a surface
Monoket Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Monoket
Isosorbide mononitrate
1993
188

Effectiveness

How Monoket Affects PatientsIsosorbide mononitrate is a medication used to prevent and manage angina. It relaxes the blood vessels, allowing more oxygen and blood to reach the heart. This reduces the work the heart has to do and prevents chest pain. Isosorbide mononitrate also relaxes other types of smooth muscles, such as those in the esophagus and bile ducts. Taking it usually provides relief from chest pain within an hour, and the effects can last up to 12 hours.
How Monoket works in the bodyIsosorbide mononitrate works by releasing nitric oxide, which is a gas that helps blood vessels relax and widen. This process is triggered by an increase of cyclic GMP, which activates protein kinases. These protein kinases then reduce the amount of calcium in the cells, which leads to the relaxation of smooth muscle cells and blood vessels widening.

When to interrupt dosage

The proposed dose of Monoket is contingent upon the indicated condition. The measure of dosage is contingent upon the technique of administration (e.g. Tablet or Tablet, extended release) as specified in the table below.
Condition
Dosage
Administration
Coronary Disease
120.0 mg, , 30.0 mg, 60.0 mg, 20.0 mg, 10.0 mg
, Tablet, extended release, Oral, Tablet, extended release - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral
Chest Pain
120.0 mg, , 30.0 mg, 60.0 mg, 20.0 mg, 10.0 mg
, Tablet, extended release, Oral, Tablet, extended release - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral

Warnings

Monoket has three contra-indications, so it should not be taken while enduring any of the circumstances outlined in the table below.Monoket Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Isosorbide Mononitrate may interact with Pulse Frequency
There are 20 known major drug interactions with Monoket.
Common Monoket Drug Interactions
Drug Name
Risk Level
Description
Riociguat
Major
Isosorbide mononitrate may increase the hypotensive activities of Riociguat.
Sildenafil
Major
The risk or severity of hypotension can be increased when Isosorbide mononitrate is combined with Sildenafil.
Abacavir
Minor
Isosorbide mononitrate may decrease the excretion rate of Abacavir which could result in a higher serum level.
Acebutolol
Minor
The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Acebutolol.
Aclidinium
Minor
Isosorbide mononitrate may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Monoket Toxicity & Overdose RiskThe lowest toxic dose of isosorbide mononitrate in rats is 2010mg/kg and 1771mg/kg in mice. Overdosing on isosorbide mononitrate can cause vasodilation, low blood pressure, increased intracranial pressure, vertigo, palpitations, visual disturbances, nausea, vomiting, syncope, air hunger, sweating, heart blocks and bradycardia, paralysis, coma, seizures, and death. To manage an overdose, it is recommended to elevate the patient's legs and give them intravenous fluids like normal saline. Dialysis may also be used to

Monoket Novel Uses: Which Conditions Have a Clinical Trial Featuring Monoket?

11 active trials are presently assessing the effectiveness of Monoket in relieving Chest Pain.
Condition
Clinical Trials
Trial Phases
Coronary Disease
1 Actively Recruiting
Not Applicable
Chest Pain
2 Actively Recruiting
Not Applicable, Phase 2, Phase 3

Patient Q&A Section about monoket

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is isosorbide used for?

"Isosorbide is used to manage chest pain in people with coronary artery disease."

Answered by AI

Is it OK to take isosorbide at night?

"This medicine works best if you space out your doses throughout the day, with a "drug-free" period of time in between each dose. Your doctor will schedule your doses to make sure there is enough time in between each dose for the medicine to work properly."

Answered by AI

What is monoket used for?

"This medication is used to prevent chest pain in patients with coronary artery disease. It belongs to a class of drugs known as nitrates. It works by relaxing and widening blood vessels so blood can flow more easily to the heart."

Answered by AI

What are the side effects of isosorbide mononitrate?

"The following are symptoms of a heart attack: an abnormal heart sound, a decrease or absence of body movement, pain in the arm, back, or jaw, black or tarry stools, bladder pain, bleeding after defecation, blood in the urine or stools, and body aches or pain."

Answered by AI

Clinical Trials for Monoket

Image of Columbia University Medical Center/ NewYork Presbyterian Hospital in New York, United States.

CTO PCI for Chronic Total Occlusions

18+
All Sexes
New York, NY
Following unsuccessful CTO crossing a CTO modification procedure is sometimes performed. CTO PCI registries where plaque modification has been performed in some patients, report this to be safe, and associated with higher success rates at subsequent attempts. It has never been investigated whether a planned investment procedure, with an intention that both the initial and staged completion PCI are of shorter duration, could improve safety and efficacy. The investigators hypothesize that 1. A planned investment procedure in the treatment of CTOs will be associated with improved patient safety 2. A planned investment procedure will be associated with improved cumulative procedure success rates 3. A planned two stage procedure will be associated with improved patient experience
Waitlist Available
Has No Placebo
Columbia University Medical Center/ NewYork Presbyterian HospitalMargaret B Mcentegart, PhD
Image of National Institutes of Health Clinical Center in Bethesda, United States.

Low SAR MRI Scans for Coronary Heart Disease

18 - 100
All Sexes
Bethesda, MD
Background: Researchers are testing version of a system known as a magnetic resonance imagining (MRI) scanner that uses strong magnetic fields, radio waves and the like to create images of the organs in the body. It uses lower energy levels than other MRI scanners. This may help scan people with metal devices in their body, or in invasive heart procedures using metal tools. Objective: To test a new MRI scanner and software changes to create better pictures. Eligibility: People with disease and healthy volunteers, ages 18 and older. Design: Participants will be screened with blood tests. Participants may have both the new MRI and a conventional MRI or only the new one. If 2 are done, they must be within 60 days. For both MRI versions, participants lie on a table that slides into a large tube. During scans, they will hold their breath for up to 20 seconds at a time. Heart activity will be measured by wires connected to pads on the skin. A flexible belt may be used to monitor their breathing. They will be in the scanner up to 2 hours. Participants can agree to have a dye called gadolinium injected into their arm during the scan. This brightens the pictures. Participants can agree to take a drug called a vasodilator. This helps detect areas of the heart with abnormal blood supply. Scans of the heart are taken before, during, and after they get the medicine. The drug may cause temporary chest pain or shortness of breath. They may get other drugs to relieve these symptoms. Sponsoring Institution: National Heart, Lung, and Blood Institute
Recruiting
Has No Placebo
National Institutes of Health Clinical CenterAdrienne E Campbell, Ph.D.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security